Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Luis Buzon Martin

Chief department

Spain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Spain

About

Dr. Luis Buzon Martin is the Chief of the Department at Hospital de Burgos, Spain. His research primarily focuses on HIV treatment regimens, particularly involving Dolutegravir in combination with Rilpivirine and Lamivudine. Additionally, he has contributed to studies on COVID-19 prevention in healthcare settings. Dr. Buzon Martin's work emphasizes the safety and efficacy of innovative therapeutic strategies in complex patient populations.

Articles (18)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (5)

Jesús Rodríguez-Baño

Professor

Universidad de Sevilla

SPAIN

View details

Jara Llenas-García

Universidad Miguel Hernández de Elche

SPAIN

View details

Alfonso Cabello-Ubeda

Jefe Asociado

Hospital Universitario Fundación Jiménez Díaz

SPAIN

View details

Mar Masiá

Head

SPAIN

View details

Francisco Fanjul

Associate professor

Universitat de les Illes Balears

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Luis Buzon Martin

Research Interests

Make your next move.

Explore related searches

About

Articles (18)

Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort

Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir + Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort

Resistance Framing, Temporal Risk Assumptions, and Public Health Priorities in the Long-Acting Antiretroviral Era

Long‐acting cabotegravir and rilpivirine in people with HIV and obesity: Real‐world outcomes from the RELATIVITY cohort

A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead

Why Tenofovir/Dolutegravir/Lamivudine if We Might Use Dolutegravir/Lamivudine

Reasons Against Routine Determination of Plasma Trough Levels in People With HIV Treated With Intramuscular Long Acting Cabotegravir and Rilpivirine as of Today

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)

A predictive model of immune recovery for DTG+3TC and DTG plus RPV used as switching strategies in HIV plus patients

Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers

Dolutegravir plus rilpivirine: benefits beyond viral suppression DORIPEX retrospective study

The secret in his eyes

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review

Collaborators (5)

Jesús Rodríguez-Baño

Jara Llenas-García

Alfonso Cabello-Ubeda

Mar Masiá

Francisco Fanjul

Make your next move.